JP2010519224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519224A5 JP2010519224A5 JP2009550160A JP2009550160A JP2010519224A5 JP 2010519224 A5 JP2010519224 A5 JP 2010519224A5 JP 2009550160 A JP2009550160 A JP 2009550160A JP 2009550160 A JP2009550160 A JP 2009550160A JP 2010519224 A5 JP2010519224 A5 JP 2010519224A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cytarabine
- leukemia
- daunorubicin
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 229960000684 Cytarabine Drugs 0.000 claims 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 3
- 229960000975 Daunorubicin Drugs 0.000 claims 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010001019 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 229940107161 Cholesterol Drugs 0.000 claims 2
- 101710040861 DCN Proteins 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 208000005749 Leukemia, Promyelocytic, Acute Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 210000002381 Plasma Anatomy 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (7)
- ヒトを対象とする白血病を治療するための方法において使用する、シタラビン対ダウノルビシンが約５：１の固定したモル比である、シタラビンとダウノルビシンから実質的になる医薬組成物であって、
該方法は、シタラビンが約１３４ｍｇ／ｍ ２ の単回投与で供給され、投与サイクルを通じて約４０２ｍｇ／ｍ ２ の合計量で供給される投与サイクルにおいて、８時間以下の期間にわたり該組成物を単回投与で静脈内投与することから実質的になり、
固定した比は少なくとも４時間血漿中で維持され、そして
固定した、非拮抗モル比のシタラビンとダウノルビシンは、ＤＳＰＣ、ＤＳＰＧおよびコレステロールから形成されるリポソーム内に被包される、前記組成物。 - ３時間以下で投与される、請求項１に記載の組成物。
- ９０分間以下で投与される、請求項２に記載の組成物。
- 前記リポソームが７：２：１のモル比でＤＳＰＣ、ＤＳＰＧおよびコレステロールを含む、請求項１〜３のいずれかに記載の組成物。
- 投与サイクルの１、３および５日に各用量の組成物を投与する、請求項１〜４のいずれかに記載の組成物。
- 白血病が、急性リンパ性白血病（ＡＬＬ）、急性骨髄性白血病（ＡＭＬ）または急性前骨髄球白血病（ＡＰＬ）である、請求項１〜５のいずれかに記載の使用。
- 前記対象が少なくとも１種の抗癌投薬計画を以前に受けている、請求項１〜６のいずれかに記載の使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90177207P | 2007-02-16 | 2007-02-16 | |
| US60/901,772 | 2007-02-16 | ||
| US96519607P | 2007-08-17 | 2007-08-17 | |
| US60/965,196 | 2007-08-17 | ||
| PCT/US2008/054168 WO2008101214A2 (en) | 2007-02-16 | 2008-02-15 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519224A JP2010519224A (ja) | 2010-06-03 |
| JP2010519224A5 true JP2010519224A5 (ja) | 2011-04-07 |
| JP5314600B2 JP5314600B2 (ja) | 2013-10-16 |
Family
ID=39690832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550160A Active JP5314600B2 (ja) | 2007-02-16 | 2008-02-15 | 造血器癌および増殖性疾患の治療のための固定した薬物比 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20100303895A1 (ja) |
| EP (3) | EP3300601B1 (ja) |
| JP (1) | JP5314600B2 (ja) |
| KR (2) | KR20100014441A (ja) |
| CN (1) | CN105998046A (ja) |
| AU (1) | AU2008216083B2 (ja) |
| CA (1) | CA2678332C (ja) |
| CY (1) | CY1119631T1 (ja) |
| DK (2) | DK3300601T3 (ja) |
| ES (2) | ES2650167T3 (ja) |
| FR (1) | FR22C1034I2 (ja) |
| HK (1) | HK1253378A1 (ja) |
| HR (1) | HRP20220428T3 (ja) |
| HU (2) | HUE058334T2 (ja) |
| NL (1) | NL301185I2 (ja) |
| NO (1) | NO2120568T3 (ja) |
| PL (2) | PL3300601T3 (ja) |
| PT (2) | PT3300601T (ja) |
| SI (1) | SI3300601T1 (ja) |
| WO (1) | WO2008101214A2 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100075937A1 (en) * | 2008-09-24 | 2010-03-25 | Hollis-Eden Pharmaceuticals, Inc. | Patient populations and treatment methods |
| CN104114156A (zh) | 2011-10-21 | 2014-10-22 | 切拉托尔制药公司 | 冻干脂质体 |
| US20140154304A1 (en) * | 2012-11-30 | 2014-06-05 | Boehringer Ingelheim International Gmbh | Combination therapy with volasertib |
| WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| JP6976941B2 (ja) * | 2015-11-11 | 2021-12-08 | セレーター ファーマシューティカルズ インコーポレイテッド | 白血病に罹患している対象の治療レジメンを選択するためのアッセイ及び方法 |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2019023873A1 (zh) * | 2017-07-31 | 2019-02-07 | 江苏竞诺择生物医药科技有限公司 | 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物 |
| AU2019350759A1 (en) * | 2018-09-25 | 2021-04-22 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| JP2022514463A (ja) | 2018-12-04 | 2022-02-14 | デル－ヤン ティエン， | 抗がん剤の送達のための立体錯体 |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| MXPA05004777A (es) * | 2002-11-06 | 2005-07-22 | Celgene Corp | Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos. |
| US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| EP1575582A4 (en) * | 2002-11-06 | 2009-03-11 | Wyeth Corp | COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME |
| US8022279B2 (en) * | 2004-04-22 | 2011-09-20 | Celator Pharmaceuticals, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
| SE0402025D0 (sv) | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| WO2007076117A2 (en) | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
-
2008
- 2008-02-15 PL PL17200498T patent/PL3300601T3/pl unknown
- 2008-02-15 ES ES08730048.9T patent/ES2650167T3/es active Active
- 2008-02-15 DK DK17200498.8T patent/DK3300601T3/da active
- 2008-02-15 US US12/526,930 patent/US20100303895A1/en not_active Abandoned
- 2008-02-15 WO PCT/US2008/054168 patent/WO2008101214A2/en active Application Filing
- 2008-02-15 ES ES17200498T patent/ES2909903T3/es active Active
- 2008-02-15 DK DK08730048.9T patent/DK2120568T3/en active
- 2008-02-15 JP JP2009550160A patent/JP5314600B2/ja active Active
- 2008-02-15 US US12/032,583 patent/US8092828B2/en active Active
- 2008-02-15 CN CN201610324431.2A patent/CN105998046A/zh active Pending
- 2008-02-15 AU AU2008216083A patent/AU2008216083B2/en active Active
- 2008-02-15 KR KR1020097019393A patent/KR20100014441A/ko active Application Filing
- 2008-02-15 EP EP17200498.8A patent/EP3300601B1/en active Active
- 2008-02-15 PT PT172004988T patent/PT3300601T/pt unknown
- 2008-02-15 SI SI200832194T patent/SI3300601T1/sl unknown
- 2008-02-15 KR KR20157007810A patent/KR20150038752A/ko active Search and Examination
- 2008-02-15 HU HUE17200498A patent/HUE058334T2/hu unknown
- 2008-02-15 NO NO08730048A patent/NO2120568T3/no unknown
- 2008-02-15 EP EP08730048.9A patent/EP2120568B1/en not_active Revoked
- 2008-02-15 PT PT87300489T patent/PT2120568T/pt unknown
- 2008-02-15 PL PL08730048T patent/PL2120568T3/pl unknown
- 2008-02-15 EP EP22150734.6A patent/EP4046640A1/en active Pending
- 2008-02-15 CA CA2678332A patent/CA2678332C/en active Active
- 2008-02-15 HR HRP20220428TT patent/HRP20220428T3/hr unknown
-
2017
- 2017-11-29 CY CY20171101251T patent/CY1119631T1/el unknown
-
2018
- 2018-10-03 HK HK18112675.7A patent/HK1253378A1/zh unknown
-
2022
- 2022-07-05 NL NL301185C patent/NL301185I2/nl unknown
- 2022-07-05 FR FR22C1034C patent/FR22C1034I2/fr active Active
- 2022-07-07 HU HUS2200032C patent/HUS2200032I1/hu unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519224A5 (ja) | ||
| JP2008517991A5 (ja) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| JP2008540364A5 (ja) | ||
| AR031978A1 (es) | Formas de dosificacion de liberacion sostenida, el uso de las mismas para la manufactura de un medicamento para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia y una composicion | |
| JP2009536147A5 (ja) | ||
| JP2006504795A5 (ja) | ||
| JP2017515913A5 (ja) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2009525343A5 (ja) | ||
| JP2007533670A5 (ja) | ||
| JP2010525050A5 (ja) | ||
| JP2001517705A5 (ja) | ||
| JP2010540616A5 (ja) | ||
| JP2009269923A5 (ja) | ||
| ZA200107920B (en) | Apomorphine and sildenafil composition. | |
| CA2582452A1 (en) | Pegylated liposomal doxorubicin in combination with ecteinascidin 743 | |
| CN106421793A (zh) | 用于治疗中枢介导的恶心及呕吐的组合物及方法 | |
| JP2006513184A5 (ja) | ||
| JP2009543885A5 (ja) | ||
| CN105682653A (zh) | 新型2，4-二硝基苯酚制剂和使用其的方法 | |
| JP2011500589A5 (ja) | ||
| JP2002540148A5 (ja) | ||
| JP2006503095A5 (ja) |